Scorpion Therapeutics unveils promising Phase 1/2 clinical data for STX-478 in advanced solid tumors

Scorpion Therapeutics, Inc. has presented initial clinical data from its Phase 1/2 trial of STX-478, a mutant-selective PI3Kα inhibitor for the treatment of advanced solid ... Read More